Ultimately, it is anticipated that CMS will further expand the use of reimbursable RTM beyond respiratory and MSK care and incorporate patient-reported information as a requirement for reimbursement of certain remote services.
Through apps, pharmaceutical companies can actually influence patient adherence and mindset after that patient has been prescribed that company's medication by their physician.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
By placing the power to detect atrial fibrillation into the hands of 6 billion global smartphone users, validation of further physiological parameters will be expedited and the subsequent adoption of this technology into DTx will enable the low-cost tools required to remove barriers to care and improve heart health across the globe.
A panel discussion on the future of digital medicine highlighted some of the collaborations taking place between pharma companies and digital health, as well as some of the challenges facing the push towards mainstream implementation.
Operational efficiency and visibility brought on by digital transformation can help improve how pharmaceutical manufacturers do their critical part in improving equitable access and availability of medicine around the world.
A webinar sponsored by Twilio will share predictions for driving personalized care and engagement in healthcare and life sciences in 2022.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The Series D round of funding makes Biofourmis a unicorn valued at $1.3 billion. CEO and founder Kuldeep Singh Rajput said that the new capital will be used to expand his company’s remote-monitoring technologies and continue development of digital therapeutics, both as companions to traditional drugs and as monotherapies.
In the U.S., EndeavorRx has been cleared to help in improving attention function as measured by computer-based testing in children ages 8-12 years who have primarily inattentive or combined-type ADHD who struggle with maintaining attention.
The company got a breakthrough device designation for its app-based program for alcohol use disorder, reset-A. Pear currently has FDA-cleared digital therapeutics to address opioid use and substance use disorders.
Click Therapeutics is developing digital therapeutics for depression, insomnia and other conditions. It plans to use the funds to commercialize its therapeutics, through partnerships with pharmaceutical companies including Otsuka.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
VCs at MedCity INVEST Digital Health said there’s no shortage of interesting digital health companies, even ones that can prove their innovations are effective. The challenge is winning over insurers and physicians, and finding payment models that work.
Luminopia, a startup with a digital therapeutic for amblyopia, or lazy eye, recently published the results of a phase 3 study showing its TV-based treatment can improve vision in kids’ non-dominant eye. Patients don a headset where images are altered to make them use both eyes.
Neuroglee recently raised $10 million in funding and struck a partnership with Mayo Clinic. It’s building a digital therapeutic and virtual programs for people with mild cognitive impairment.
The company recently finished a study showing patients in the U.K. who used both Sleepio’s app and therapy saw improvements in anxiety and depression compared to people who used therapy alone. But the study also had several limitations.
The startup is working with Curebase to launch five clinical trials to test its VR-based therapeutic for chronic pain. They plan to enroll a total of more than 2,000 people.